REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a solicitation reminding investors of a class action lawsuit against Replimune Group, Inc. for alleged violations of the Securities Exchange Act. The complaint alleges the company made false statements regarding FDA study design concerns for its RP1-104 study and submitted data from an unplanned analysis.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.